• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

UCHL1 protects against ischemic heart injury via activating HIF-1 α signal pathway
Redox Biol. 2022 Mar 18;52:102295. doi: 10.1016/j.redox.2022.102295. Online ahead of print.ABSTRACTUbiquitin carboxyl-terminal esterase L1 (UCHL1) has been thought to be a neuron specific protein and shown to play critical roles in Parkinson's Disease and stroke via de-ubiquiting and stabilizing key pathological proteins, such as α-synuclein. In the present study, we found that UCHL1 was significantly increased in both mouse and human cardiomyocytes following myocardial infarction (MI). When LDN-57444, a pharmacological inhibitor of UCHL1, was used to treat mice subjected to MI surgery, we found that administration of LDN...
Source: Cancer Control - March 27, 2022 Category: Cancer & Oncology Authors: Bingchuan Geng Xiaoliang Wang Ki Ho Park Kyung Eun Lee Jongsoo Kim Peng Chen Xinyu Zhou Tao Tan Chunlin Yang Xunchang Zou Paul M Janssen Lei Cao Lei Ye Xuejun Wang Chuanxi Cai Hua Zhu Source Type: research

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research

Neural stem cells promote glioblastoma formation in nude mice
ConclusionsThese results imply the potential role that NSCs play in speeding up tumor formation in the process of glioblastoma relapse, providing the basis for dealing with newly diagnosed glioblastoma patients, which may help postpone the recurrence of glioblastoma as far as possible through preprocessing the tumor-adjacent SVZ tissue.
Source: Clinical and Translational Oncology - April 2, 2019 Category: Cancer & Oncology Source Type: research

Cardiac Complications in the Adult Bone Marrow Transplant Patient
AbstractPurpose of ReviewDue to advancements in oncologic treatment strategies and techniques, the number of survivors who have undergone hematopoetic stem cell transplant (HCT) continues to increase in the United States; this number is projected to reach 502,000 by the year 2030. There is significant interest within the field of cardio-oncology to identify cardiotoxicity and cardiovascular disease in the HCT population. Epidemiologic studies analyzing both short- and long-term cardiovascular effects, risk stratification modeling, cardioprotective strategies, and expert consensus documents for cardiotoxicity surveillance r...
Source: Current Oncology Reports - March 1, 2019 Category: Cancer & Oncology Source Type: research

New Insights from Studies of Clonal Hematopoiesis.
Abstract Clonal hematopoiesis (CH) describes an asymptomatic expansion of blood cells descended from a single hematopoietic stem cell. Recent studies have shown that CH increases in frequency with aging, and is often driven by somatic mutations in genes that are recurrently mutated in hematologic malignancies. When CH is associated with a mutation in a leukemia-associated gene at a variant allele frequency of 0.02 or greater, it is termed "clonal hematopoiesis of indeterminate potential" (CHIP).  CHIP has a 0.5-1% risk per year of progression to hematological neoplasia, and increases both all-cause mortality and ...
Source: Clinical Cancer Research - April 27, 2018 Category: Cancer & Oncology Authors: Gibson CJ, Steensma DP Tags: Clin Cancer Res Source Type: research

Therapeutic effects of umbilical cord blood plasma in a rat model of acute ischemic stroke.
This study provides valuable insights into the development of a safe, effective, and cell-free strategy for the treatment of ischemic brain damage and a much-needed alternative for patients who are ineligible for thrombolytic therapy. PMID: 27816964 [PubMed - as supplied by publisher]
Source: Oncotarget - November 8, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke.
In conclusion, xenogenic ADMSC/ADMSC-derived exosome therapy was safe and offered the additional benefit of reducing BIZ and improving neurological function in rat AIS. PMID: 27793019 [PubMed - as supplied by publisher]
Source: Oncotarget - October 31, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
Authors: Thériault P, Le Béhot A, ElAli A, Rivest S Abstract Stroke is associated with neuroinflammation, neuronal loss and blood-brain barrier (BBB) breakdown. Thus far, recombinant tissue-type plasminogen activator (rtPA), the only approved treatment for acute ischemic stroke, increases the risk of intracerebral hemorrhage and is poorly efficient in disaggregating platelet-rich thrombi. Therefore, the development of safer and more efficient therapies is highly awaited. Encouraging neuroprotective effects were reported in mouse models of ischemic stroke following administration of erythropoietin (EPO). However, ...
Source: Oncotarget - June 2, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab
Publication date: Available online 2 December 2015 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Sara Khodor, Miguel Castro, Colin McNamara, Chakra P. Chaulagain Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by microvascular aggregation of platelets and fibrin strands causing thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction. TTP can develop as a result of a deficiency in ADAMTS13 enzyme activity due to either a genetic defect or, more commonly, the development of anti-ADAMTS13 autoantibodies. TTP can also be associated with pregnancy, organ t...
Source: Hematology Oncology and Stem Cell Therapy - March 7, 2016 Category: Cancer & Oncology Source Type: research

Central Nervous System Complications and Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
Conclusions The occurrence of CNSCs after ALLO-HSCT was associated with reduced survival. Identifying patients at risk, monitoring, early detection and management of CNSCs post ALLO-HSCT is needed to improve outcomes. Teaser This retrospective study of 351 patients, who have undergone allogeneic hematopoietic stem cell transplantation between 2002 and 2011 at the University of Nebraska Medical Center, demonstrated 12% incidence of central nervous system complications. The most common complications included posterior reversible encephalopathy syndrome (40%), stroke or transient ischemic attack (24%), seizures (20%), and inf...
Source: Clinical Lymphoma Myeloma and Leukemia - June 30, 2015 Category: Cancer & Oncology Source Type: research